These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32563568)

  • 21. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
    Puccetti L; Sammartano V; Calzoni P; Bacchiarri F; Santoni A; Fineschi D; Bocchia M
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):54-58. PubMed ID: 35049019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
    Sprynger M
    Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
    Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
    Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in anticoagulant prescribing: a review of local policies in English primary care.
    Ho KH; van Hove M; Leng G
    BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intracranial hemorrhage due to pulmonary thromboembolism in heparin therapy and therapeutic management of patients hospitalized with massive pulmonary embolism after discharge].
    Beşli F; Keçebaş M; Alişir MF; Güngören F
    Turk Kardiyol Dern Ars; 2013 Apr; 41(3):228-32. PubMed ID: 23703559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
    de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
    Yamazaki H; Yagi S; Torii Y; Amano R; Oomichi Y; Sangawa T; Fukuda D; Kadota M; Ise T; Ueno R; Hara T; Kusunose K; Matsuura T; Tobiume T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Akaike M; Sata M
    J Cardiol; 2018 Mar; 71(3):305-309. PubMed ID: 29100817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.
    Bauersachs R; Agnelli G; Gitt AK; Monreal M; Mismetti P; Willich SN; Laeis P; Fronk EM; Bramlage P; Cohen AT;
    Thromb Res; 2017 Sep; 157():181-188. PubMed ID: 28780343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-Analysis of Direct Oral Anticoagulants Compared With Vitamin K Antagonist for Left Ventricle Thrombus.
    Mir T; Sattar Y; Attique HB; Hussain T; Alraies MC; Sheikh M; Qureshi WT
    Cardiovasc Revasc Med; 2022 Feb; 35():141-146. PubMed ID: 33722539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding.
    Xu Y; Schulman S; Dowlatshahi D; Holbrook AM; Simpson CS; Shepherd LE; Wells PS; Giulivi A; Gomes T; Mamdani M; Frymire E; Khan S; Johnson AP;
    Thromb Res; 2019 Oct; 182():12-19. PubMed ID: 31434018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.